CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicines.   Editas ...

Editas Medicine, Inc. (NASDAQ:EDIT) Barclays 26th Annual Global Healthcare Conference March 13, 2024 2:05 PM ET Company Participants Gilmore O'Neil - Chief Executive Officer Erick Lucera - Chief Financial Officer Conference Call Participants Gena Wang - Barclays Gena Wang Good afternoon, everyone, and welcome to Barclays Global Healthcare Conference. My name is Gena Wang. I cover the US mid-cap biotech. It is my great pleasure to introduce our next presenting company, Editas Medicine. With us today we have ...

Editas Medicine, Inc. (NASDAQ:EDIT) Leerink Partners Global Biopharma Conference March 12, 2024 10:40 AM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - Conference Call Participants Mani Foroohar - Leerink Mani Foroohar Good morning, everyone. Welcome back to the 2024 Global Biopharma Conference, Inaugural Miami Conference. So welcome everybody down. I am Mani Foroohar, Senior Analyst Genetic Medicines. And I'm very fortunate to be hosting the team from Editas Medicine. How are you doing? Gilm ...

With Citigroup analyst Samantha Semenkow calling on Feb. 29 for shares of Editas Medicine (EDIT -0.66%) to rise from their current price near $10 to reach $16 -- an increase of 45% over her prior estimate -- there's a clear consensus about the stock forming on Wall Street. Based on Semenkow's price target, which is effectively the same as the consensus average price target across analysts following the stock, Editas Medicine is looking at a 70% bump.It could happen. Here's why.This company just got a huge b ...

Editas Medicine, Inc. (NASDAQ:EDIT) TD Cowen 44th Annual Healthcare Conference March 4, 2024 12:50 PM ET Company Participants Gilmore O'Neill - CEO Erick Lucera - CFO Conference Call Participants Phil Nadeau - TD Cowen Phil Nadeau Good afternoon and welcome once again to TD Cowen’s 44th Annual Healthcare Conference. I'm Phil Nadeau, one of Cowen’s biotech analysts, and it's my pleasure to moderate a fireside chat with Editas. We have with us today, Gilmore O'Neill, CEO and Erick Lucera, CFO. Hand it over ...

Although equities have performed pretty well in the past three years, many somewhat speculative and unprofitable stocks have struggled as investors have turned their attention away from such corporations. That's the case with Editas Medicine (EDIT -2.47%), a clinical-stage gene editing-focused biotech company.However, many analysts on Wall Street have high hopes for the stock. Editas Medicine's average price target of $15.64 implies an upside of about 55% over its stock price of $10.06 (as of writing). Can ...

Shares of Editas Medicine (EDIT 4.67%) charged sharply higher this week, soaring as much as 41.6%, according to data from S&P Global Market Intelligence. By the time the market closed on Friday, the stock was still up 34.8%.The catalyst that vaulted the gene editing specialist higher was the company's quarterly report, which included a surprise announcement.Alignment with the FDAOn Wednesday, Editas Medicine released its fourth-quarter results, which were better than investors had hoped. The company generat ...

Editas Medicine, Inc. (EDIT) incurred a loss of 23 cents per share in the fourth quarter of 2023, narrower than the Zacks Consensus Estimate of a loss of 52 cents. The company had reported a loss of 88 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $60 million in the reported quarter, up significantly from $6.5 million reported in the year-ago quarter. The reported figure beat the Zacks Consensus Estimate o ...

Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2023 Earnings Conference Call February 28, 2024 8:00 AM ET Company Participants Cristi Barnett - Corporate Communications and IR Gilmore O'Neill - CEO Baisong Mei - CMO Erick Lucera - CFO Linda Burkly - CSO Caren Deardorf - Chief Commercial and Strategy Officer Conference Call Participants Joon Lee - Truist Securities Samantha Semenkow - Citi Brian Cheng - JPMorgan Greg Harrison - Bank of America Mani Foroohar - Leerink Max Skor - Morgan Stanley Gena Wang - Barclays Da ...

Editas Medicine (EDIT) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.88 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 55.77%. A quarter ago, it was expected that this genome editing company would post a loss of $0.64 per share when it actually produced a loss of $0.55, delivering a surprise of 14.06%.Over the last four quarters, the compa ...